



# DIVERSITY, EQUITY AND INCLUSION IN CLINICAL TRIALS

©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

US-NONO-00270  
March 2022

**EMD  
SERONO**

In the United States, people of color make up 43% of the population<sup>1</sup>,

## YET THERE IS SYSTEMATIC UNDER-REPRESENTATION IN CLINICAL TRIALS.

Only  
**8%**  
of clinical trial participants are **Black** despite making up  
**14%**  
of the US population<sup>2</sup>

Only  
**11%**  
of clinical trial participants are **Latino** despite making up  
**19%**  
of the US population<sup>2</sup>

**WITHOUT DIVERSE REPRESENTATION,** researchers are not able to identify or mitigate **different drug effects** in different populations.<sup>2</sup>

1. 2020 US census data. <https://www.census.gov/en.html>. Accessed March 11, 2022.

2. FDA Snapshot data: Participation in Clinical Trials by Subpopulation\* for New Molecular Entities and Therapeutic Biologics Approved by FDA in 2020, <https://www.fda.gov/media/145718/download>. Accessed March 11, 2022.

**There are four  
key barriers to  
participation in  
clinical trials for  
people of color...**

**1**

**Awareness**

**2**


**Access**

**3**

**Recruitment**

**4**

**Screening**



# Our approach to diversity, equity and inclusion in clinical trials

## OUR objective

To **better reflect** in our clinical trials and provide benefit to the **diverse patient populations** that are in need and would most likely use our drug(s) for treating their disease

Our focus includes, but is not limited to, **age, sex, gender, gender identity, race, ethnicity, religion, and their intersections**



## OUR COMMITMENT

To **address key barriers and limitations** negatively impacting the diversity, equity and inclusion of minority populations in clinical trials with an end-to-end strategic mindset

# WE USE FOUR KEY PILLARS

To create tactical and targeted efforts for an inclusive approach

1

**Partner with  
HCPs who are  
diverse or  
provide  
treatment  
to diverse  
communities**

2


**Invest in  
community  
education and  
outreach –  
spread  
awareness**

3

**Facilitate  
patient  
participation  
in clinical  
research**

4


**Leverage  
protocol  
design and the  
use of real-  
world data**



# OUR DIVERSITY, EQUITY & INCLUSION STRATEGY IS ALIGNED AND STRENGTHENED BY MULTIPLE INDUSTRY EFFORTS

An Inclusive, Overarching and Study Specific Approach

## Diversity, Equity & Inclusion in Clinical Trials Strategy



# FOUR KEY PILLARS

## Identifying key tactical and targeted efforts for an inclusive approach



### **1 Partner with HCPs who are Diverse or Provide Care to Diverse Communities**

Partner with healthcare providers who provide care to underserved and racial/ethnic populations to ensure comprehensive patient representation when developing treatments.



### **2 AWARENESS & COMMUNITY OUTREACH**

Invest in community education, outreach and building trust within diverse communities to enhance clinical trial awareness and participation in the patient and medical community.




### **3 FACILITATE PATIENT PARTICIPATION IN CLINICAL RESEARCH**

Ensure that trial participants represent target populations that are affected by the disease.



### **4 PROTOCOL DESIGN AND THE USE OF REAL WORLD DATA**

Design inclusive clinical trials that follow internal and external guidance and best practices related to diversity of patients in clinical trials while utilizing real world data.





LET'S TALK!



HOW DO WE **shape our collaboration** in  
DIVERSITY, EQUITY AND INCLUSION?

